Chlamydia 60 Kda CRMP antigens and vaccine uses

Details Chlamydia 60 Kda CRMP antigens and vaccine uses Chlamydia 60 Kda CRMP antigens and vaccine uses

2007-09-11

2009-12-08

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07629327

ABSTRACT:
The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain ofChlamydia, specificallyC. pneumoniae. The vaccine and method employ a 60 kDa cysteine-rich membrane protein of a strain ofChlamydia pneumoniae. Modifications are possible within the scope of this invention.

REFERENCES:
patent: 4879213 (1989-11-01), Fox et al.
patent: 5776746 (1998-07-01), Denney, Jr.
patent: 6020191 (2000-02-01), Scaria et al.
patent: 6255082 (2001-03-01), Lizardi
patent: 6521745 (2003-02-01), Murdin et al.
patent: 6559294 (2003-05-01), Griffais et al.
patent: 6693087 (2004-02-01), Murdin et al.
patent: 6808713 (2004-10-01), Murdin et al.
patent: 6822071 (2004-11-01), Stephens et al.
patent: 7019125 (2006-03-01), Murdin et al.
patent: 7070792 (2006-07-01), Murdin et al.
patent: 7081245 (2006-07-01), Murdin et al.
patent: 2002/0082402 (2002-06-01), Murdin et al.
patent: 2002/0094340 (2002-07-01), Murdin et al.
patent: 2002/0094965 (2002-07-01), Murdin et al.
patent: 2002/0099188 (2002-07-01), Murdin et al.
patent: 2002/0132994 (2002-09-01), Murdin et al.
patent: 2003/0100706 (2003-05-01), Murdin et al.
patent: 2004/0254130 (2004-12-01), Murdin et al.
patent: WO 9746709 (1997-12-01), None
patent: WO 9858953 (1998-12-01), None
patent: WO99/28475 (1999-06-01), None
patent: WO00/24765 (2000-05-01), None
patent: WO00/27994 (2000-05-01), None
patent: WO00/34483 (2000-06-01), None
patent: WO00/37494 (2000-06-01), None
patent: WO00/46359 (2000-08-01), None
patent: WO00/66739 (2000-11-01), None
patent: WO01/21804 (2001-03-01), None
patent: WO01/21811 (2001-03-01), None
patent: WO01/40474 (2001-06-01), None
patent: WO01/46224 (2001-06-01), None
patent: WO01/81379 (2001-11-01), None
patent: WO01/85972 (2001-11-01), None
patent: WO02/02606 (2002-01-01), None
patent: WO02/08267 (2002-01-01), None
Grayston et al. (1995)Journal of Infectious Diseases168:1231.
Campos et al. (1995)Investigation of Ophthalmology and Visual Science36:1477.
Grayston et al (1990)Journal of Infectious Diseases161:618.
Marrie (1993)Clinical Infectious Diseases. 18:501.
Wang et al (1986)Chlamydialinfections. Cambridge University Press, Cambridge. p. 329.
Saikku et al.(1988)Lancet;ii:983.
Thom et al. (1992)JAMA268:68.
Linnanmaki et al. (1993),Circulation87:1030.
Saikku et al. (1992)Annals Internal Medicine116:273.
Melnick et al(1993)American Journal of Medicine95:499.
Shor et al. (1992)South African. Medical Journal82:158.
Kuo et al. (1993)Journal of Infectious Diseases167:841.
Kuo et al. (1993)Arteriosclerosis and Thrombosis13:1501.
Campbell et al (1995)Journal of Infectious Diseases172:585.
Chiu et al (1997)Circulation. 96(7):2144-2148.
Ramirez et al (1996)Annals of Internal Medicine125:979.
Jackson et al. Abst. K121, p. 272, 36thICAAC, Sep. 15-18, 1996, New Orleans.
Fong et al (1997)Journal of Clinical Microbiolology35:48.
Hahn DL, et al. “Evidence forChlamydia pneumoniaeinfection in steroid-dependent asthma”.Ann Allergy Asthma Immunol. Jan. 1998; 80(1): 45-49.
Hahn DL, et al. “Association ofChlamydia pneumoniaeIgA antibodies with recently symptomatic asthma”.Epidemiol Infect. Dec. 1996; 117(3): 513-517.
Bjornsson E, et al. “Serology ofChlamydiain relation to asthma and bronchial hyperresponsiveness”.Scand J Infect Dis. 1996; 28(1): 63-69.
Hahn DL. “Treatment ofChlamydia pneumoniaeinfection in adult asthma: a before-after trial”. J Fam Pract. Oct. 1995; 41(4): 345-351.
Allegra L, et al. “Acute exacerbations of asthma in adults”:role of Chlamydia pneumoniae infection. Eur Respir J. Dec. 1994; 7(12): 2165-2168.
Hahn DL, et al. “Association ofChlamydia pneumoniae(strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma”.JAMA. Jul. 10, 1991; 266(2): 225-230.
Pal et al.(1996)Infection and Immunity.64:5341.
Jones et al. (1995)Vaccine13:715.
Igietseme et al (1993)Regional Immunology5:317.
Magee et al (1993)Regional Immunology5: 305.
Landers et al (1991)Infection&Immunity59:3774.
Magee et al (1995)Infection&Immunity63:516.
Cotter et al. (1995)Infection and Immunity63:4704.
Campbell et al (1990)Infection and Immunity58:93.
McCafferty et al (1995)Infection and Immunity63:2387-9.

Affiliated with

Also associated with

Rating

Chlamydia 60 Kda CRMP antigens and vaccine uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chlamydia 60 Kda CRMP antigens and vaccine uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlamydia 60 Kda CRMP antigens and vaccine uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4094533